Skip to main content
Publish date:

New Use for J&J's Remicade

The treatment is cleared for chronic severe plaque psoriasis.

Johnson & Johnson's

(JNJ) - Get Johnson & Johnson Report

Centocor unit said U.S. regulators cleared Remicade for the treatment of adult patients with chronic severe plaque psoriasis, an inflammation of the skin.

The Food and Drug Administration approved the new use for patients who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

TheStreet Recommends

Remicade is already used to treat several other conditions, including ulcerative colitis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis.